Desloratadine PCD Pharma Franchise Company
Cafoli Lifecare offers a Desloratadine range of 4 tablet formulations, manufactured in WHO-GMP certified facilities. Distributors serving dermatology, ENT and general-practice prescribers can secure district-wise monopoly franchise rights for this second-generation antihistamine with full promotional support.
What is Desloratadine?
Desloratadine is a second-generation, non-sedating H1-antihistamine and the active metabolite of loratadine. It provides once-daily relief of allergic symptoms by selectively blocking peripheral histamine H1 receptors with minimal central sedation. Reference: PubChem - Desloratadine.
Available Forms
The Cafoli Desloratadine portfolio is offered as oral Tablets, including combinations with montelukast for allergic rhinitis. Contact us for current pack presentations and combinations.
Therapeutic Applications
Desloratadine is prescribed for allergic rhinitis (seasonal and perennial) and for chronic urticaria and other allergic skin conditions. Prescribers include dermatologists, ENT specialists, chest physicians, paediatricians and general practitioners.
Why Desloratadine is a High-Potential Molecule for Distributors
Allergic rhinitis and urticaria are extremely common year-round, and non-sedating antihistamines are first-line therapy, so desloratadine sees steady, high-frequency prescribing. Its desloratadine-montelukast combination is especially popular in respiratory-allergy practice, giving distributors dependable volume plus a premium combination line.
Why Choose Cafoli Lifecare
Cafoli Lifecare offers monopoly franchise rights, WHO-GMP certified manufacturing, DCGI-approved formulations, a network of 1000+ franchise partners across India, and free promotional inputs.
References
- PubChem: Desloratadine
- MedlinePlus: Desloratadine
- PubMed: desloratadine in rhinitis and urticaria
Our formulations of Desloratadine find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: